COMPOSITIONS AND METHODS FOR THE PREVENTION AND CONTROL OF INSULIN-INDUCED HYPOGLYCEMIA
First Claim
Patent Images
1. A pharmaceutical formulation comprising:
- insulin in an amount effective for the control of diabetes; and
glucagon in an amount effective for the prevention of hypoglycemia in a human or other mammal, wherein said pharmaceutical formulation is configured to be administered subcutaneously, and wherein a ratio of insulin to glucagon is about 1 unit of insulin to between more than 40 milliunits to 200 milliunits of glucagon.
1 Assignment
0 Petitions
Accused Products
Abstract
Pharmaceutical compositions comprising both insulin and glucagon can be administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia.
-
Citations
21 Claims
-
1. A pharmaceutical formulation comprising:
-
insulin in an amount effective for the control of diabetes; and glucagon in an amount effective for the prevention of hypoglycemia in a human or other mammal, wherein said pharmaceutical formulation is configured to be administered subcutaneously, and wherein a ratio of insulin to glucagon is about 1 unit of insulin to between more than 40 milliunits to 200 milliunits of glucagon. - View Dependent Claims (2, 3, 4, 5, 6)
-
-
7. A method of treating diabetes in a human or other mammal without inducing hypoglycemia, said method comprising:
-
administering insulin in an amount therapeutically effective for the control of diabetes, wherein said insulin is in an amount between 0.5 and 20 Units of insulin; and administering glucagon in time and an amount therapeutically effective for the prevention of hypoglycemia, wherein said glucagon is administered subcutaneously, and wherein the amount of glucagon administered is between more than 5 and less than or equal to 100 ng per kg of patient per minute of desired glucagon effectiveness. - View Dependent Claims (8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
-
-
18. A kit for the administration of glucagon and insulin in amounts to prevent hypoglycemia, said kit comprising:
-
glucagon; insulin, wherein said glucagon and insulin are in a ratio of 1-20 units of insulin to 32-480 milliunits of glucagon; a means for administering glucagon subcutaneously; and instructions for the administration of insulin and glucagon so that the glucagon prevents a hypoglycemic event. - View Dependent Claims (19, 20, 21)
-
Specification